Oestrogen receptor mutants and variants in breast cancer

European Journal of Cancer Part A

Volumn 33, Issue 8, 1997, Pages 1177-1183

  Dowsett, M ^a   Daffada, A ^a   Chan, C M W ^a   Johnston, S R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Oestrogen receptor mutants; Oestrogen receptor variants

Indexed keywords

ESTROGEN RECEPTOR;

BREAST CARCINOMA; GENE MUTATION; HUMAN; HUMAN CELL; PHENOTYPE; POINT MUTATION; PREDICTION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION;

BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION; RECEPTORS, ESTROGEN; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 0030754530     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00100-7     Document Type: Review

References (67)

1. De Sombre ER, King WJ, Green GL, Thorpe SM, Rose C, Jensen EV. Estrogen receptor studies. Laboratory investigations and clinical applications. In Jordan VC, ed. Estrogen/ Antiestrogen Action and Breast Cancer Therapy. Wisconsin, University of Wisconsin Press, 1986, 303-323.
2. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustufsson J-A. Cloning of a novel estrogen receptor expressed in rat prostrate and ovary. Proc Natl Acad Sci USA 1996, 93, 5925-5930.
3. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA sequence, expression and homology to v-erbA. Nature 1986, 320, 134-139.
4. Evans RM. The steroid of thyroid hormone receptor superfamily. Science 1988, 240, 889-895.
5. Jensen EV. Overview of the nuclear receptor family. In Parker MG, ed. Nuclear Hormone Receptors Molecular Mechanisms, Cellular Functions, Clinical Abnormalities. London, Academic Press, 1991, 1-5.
6. O'Malley BW, Connelly OM. Orphan receptors: in search of a unifying hypothesis for activation. Mol Endocrinol 1992, 6, 1359-1361.
7. Kroust A, Greene S, Argos P, et al. The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J 1986, 5, 891-897.
8. Kumar V, Green S, Stack G, Berry M, Jin J, Chambon P. Functional domains of the human oestrogen receptor. Cell 1987, 51, 941-951.
9. Ponglikitmongkol M, Green S, Chambon P. Genomic organisation for the human oestrogen receptor gene. EMBO J 1988, 7, 3385-3388.
10. Katzenellenbogen BS, Ellisten JF, Mansma FJ, Springer PA, Ziegler YS, Greene GL. Structural analysis of covalently labelled estrogen receptors by limited proteolysis and monoclonal antibody reactivity. Biochemistry 1987, 26, 2364-2373.
11. Green S, Chambon P. Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor. Nature 1987, 325, 75-78.
12. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced hormo-dimer. Cell 1988, 55, 145-156.
13. Webster NJG, Green S, Jin J-R, Chambon P. The hormone binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988, 54, 199-207.
14. Lees JA, Fawell SE, Parker MG. Identification of two transactivation domains in the mouse estrogen receptor. Nucleic Acids Res 1989, 17, 5477-5488.
15. Metzger D, White JH, Chambon P. The human oestrogen receptor functions in yeast. Nature 1988, 334, 31-36.
16. White JH, Metzger D, Chambon P. Expression and function of the human oestrogen receptor in yeast. Cold Spring Harbour Symp Quant 1988, 53, 819-828.
17. Green S, Chambon P. The oestrogen receptor: from perception to mechanism. In Parker MG, ed. Nuclear Hormone Receptors. Molecular Mechanisms, Cellular Functions, Clinical Abnormalities. London, Academic Press, 1991, 15-38.
18. Denis M, Poellinger L, Wikstroem A, Gustafsson J. Requirement of hormone for themal conversion of the glucocorticoid receptor to a DNA binding state. Nature 1988, 333, 686-688.
19. Lahooti H, Thorsen T, Aakavaag A. Phosphorylation of the estradiol receptor in MCF7 human breast cancer cells in culture. Mol Cell Endocrinol 1990, 79, 21-32.
20. Denton RR, Koozewski NJ, Notides AC. Estrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding. J Biol Chem 1992, 267, 7263-7268.
21. Ali S, Metzger D, Bornet JM, Chambon P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 1993, 12, 1153-1160.
22. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS. Phosphorylation of human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 1994, 269, 4458-4466.
23. Klein-Hitpass L, Ryffel GU, Heitlinger E, Cato ACB. A 13bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acid Res 1988, 16, 647-663.
24. Oñate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1955, 270, 1354-1357.
25. Tassett D, Tora L, Fromental C, Scheer E, Chambon P. Distinct classes of transcriptional activation domains function by different mechanisms. Cell 1990, 62, 1177-1187.
26. Berry M, Metzger S, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonist activity of the antioestrogen 4-hydroxytamoxifen. EMBO J 1990, 9, 2811-2818.
27. Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P. The cloned human estrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 1989, 8, 1891-1896.
28. Pham TA, Hwung YP, McDonnell DP, O'Malley BW. Transactivation functions facilitate the disruption of chromatin structure by estrogen receptor derivatives in vivo. J Biol Biochem 1991, 266, 18179-18187.
29. Bocquel MT, Kumar V, Stricker C, Chambon P, Gronemayer H. The contribution of the N-and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. Nucleic Acids Res 1989, 17, 2581-2595.
30. McInerney EM, Tsai M-J, O'Malley BW, Katzenellenbogen BS. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Nad Acad Sci USA 1996, 93, 10069-10073.
31. Korach KS. Insights from the study of animals lacking functional estrogen receptor. Science 1994, 226, 1524-1527.
32. Hughes MR, O'Malley BW. Genetic defects in receptors involved in disease. In Parker MG, ed. Nuclear Hormone Receptors: Molecular Mechanisms, Cellular Functions and Clinical Abnormalities. London, Academic Press, 1991, 321-353.
33. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estogen-receptor gene in a man. New Engl J Med 1994, 331, 1056-1061.
34. Mahfoudi A, Roulet E, Dawois S, Parker MG, Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 1995, 92, 4206-4210.
35. Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 1996, 10, 230-242.
36. Wolf DM, Jordan VC. The estrogen receptor from tamoxifen stimulated MCF7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994, 31, 129-138.
37. Jordan VC, Catherino WL, Wolf DM. Drug resistance to tamoxifen: mutant estrogen receptors as a potential mechanism of tamoxifen-stimulated tumor growth. Endocrine-Related Cancer 1995, 2, 45-51.
38. Andersen TI, Wooster R, Laake K, et al. Screening for ESR mutations in breast ovarian cancer patients. Human Mutat, in press.
39. Karnik PS, Kulkarni S, Liu X-P, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994, 54, 349-353.
40. Roodi N, Bailey LR, Kao W-Y, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst 1995, 87, 446-451.
41. Witschke C, Lemieux P, Wolf DM, et al. Isolation of receptor variant from premalignant breast lesions. Breast Cancer Res Treat (suppl) 1996, 37, abstr 29.
42. Daffada AAI, Dowsett MD. Tissue-dependent expression of a novel splice variant of the human oestrogen receptor. J Steroid Mol Biol 1995, 55, 413-421.
43. Murphy LC, Wang M, Coutt A, Dotzlaw H. Novel mutations in the estrogen receptor messenger RNA in human breast carcinomas. J Clin Endocrinol Metab 1996, 81, 1420-1427.
44. Murphy LC, Dotzlaw H. Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 1989, 3, 687-693.
45. Fuqua SAW, Fitzgerald SD, Chamness GC, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991, 51, 105-110.
46. Wang Y, Miksicek RJ. Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol 1991, 5, 1707-1715.
47. Fuqua SAW, Fitzgerald SD, Allred DC, et al. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 1992, 52, 483-486.
48. Castles CG, Fuqua SAW. Alterations within the estrogen receptor in breast cancer. In Pasqualini JR, Katzenellenbogen BS, eds. Hormone-dependent cancer. New York, Marcel Dekker, 1996, 81-106.
49. Pfeffer U, Fecarotta E, Vidali G. Co-expression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF7 cells. Cancer Res 1995, 55, 2158-2165.
50. Horwitz KB, Wei LL, Sedlacek SM, D'Arville CN. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res 1985, 41, 249-316.
51. Castle CG, Fuqua SAW, Klotz DM, Hill SM. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 1993, 53, 5934-5939.
52. Fuqua SAW, Wiltschke C, Castles C, Wolf D, Allred DC. A role for estrogen-receptor variants in endocrine resistance. Endocrine-Related Cancer 1995, 2, 19-25.
53. Fuqua SAW, Wolf D. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995, 35, 233-241.
54. DeFriend DJ, Howell A, Nicolson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994, 54, 408-414.
55. Daffada AAI, Johnston SRD, Smith IE, Detre S, King N, Dowsett M. Exon 5-deletion variant oestrogen receptor mRNA expression in relation to tamoxifen resistance and PgR/pS2 status in human breast cancer. Cancer Res 1995, 55, 288-293.
56. Rea D, Parker MG. Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells. Cancer Res 1996, 56, 1556-1563.
57. Dotzlaw H, Alkhalaf M, Murphy LC. Characterization of estrogen receptor variant mRNAs for human breast cancers. Mol Endocrinol 1992, 6, 773-785.
58. Koehorst SGA, Jacobs HM, Thijssen JHH, Blankenstein MA. Wild type and alternatively spliced estrogen receptor messenger RNA in human meningioma tissue and MCF7 breast cancer cells. J Steroid Biochem Mol Biol 1993, 45, 227-233.
59. McGuire WL, Chamness GC, Fuqua SAW. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991, 5, 1571-1577.
60. Fuqua SAW, Fitzgerald SD, Allred DC, et al. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumours. Cancer Res 1992, 52, 483-486.
61. Leygue E, Huang A, Murphy LC, Watson PH. Prevalence of variant messenger RNAs in human breast cancer. Cancer Res 1996, 56, 4324-4327.
62. Leygue ER, Watson PH, Murphy LC. Estrogen receptor variants in normal human mammary tissue. J Natl Cancer Inst 1996, 88, 284-290.
63. Moalli PA, Pillay S, Krett NL, Rosen ST. Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Res 1993, 53, 3877-3879.
64. Zhu X, Daffada AAI, Chan CMW, Dowsett M. Detection of an exon 3 deleted splice variant of androgen receptor messenger RNA in human breast cancer cell lines. Int J Cancer, in press.
65. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Identification of novel exon-deleted progesterone receptor variant mRNAs in human breast tissue. Biochem Biophys Res Commun 1996, 228, 63-68.
66. Sato M, Glasebrook AL, Bryant HU. Raloxifene in selective estrogen receptor modulator. J Bone Miner Metab (suppl 2) 1994, 12, S9-S20.
67. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996, 273, 1222-1225.